胃癌筛查方法与模式的现状及展望

仇祎凡 周显祝 李兆申 杜奕奇

引用本文: 仇祎凡,周显祝,李兆申,等. 胃癌筛查方法与模式的现状及展望[J]. 海军军医大学学报,2025,46(10):1336-1343. DOI: 10.16781/j.CN31-2187/R.20240309.
Citation: QIU Y, ZHOU X, LI Z, et al. Screening methods and patterns for gastric cancer: current status and prospect[J]. Acad J Naval Med Univ, 2025, 46(10): 1336-1343. DOI: 10.16781/j.CN31-2187/R.20240309.

胃癌筛查方法与模式的现状及展望

doi: 10.16781/j.CN31-2187/R.20240309
基金项目: 

“四大慢病”国家科技重大专项 2025ZD05453004;

国家自然科学基金 82470594;

国家自然科学基金 82504509;

上海市加强公共卫生体系建设三年行动计划(2023-2025年)重点学科建设项目 GWVI-11.1-21.

详细信息

Screening methods and patterns for gastric cancer: current status and prospect

Funds: 

National Major Science and Technology Project for Noncommunicable Chronic Diseases 2025ZD05453004;

National Natural Science Foundation of China 82470594;

National Natural Science Foundation of China 82504509;

Key Discipline Construction Project of Three-Year Action Plan for Strengthening Construction of Public Health System in Shanghai (2023-2025) GWVI-11.1-21.

  • 摘要: 我国是胃癌高发国家,开展大规模人群筛查对实现胃癌的早期诊疗具有重要意义。当前的实践经验表明,筛查方法和模式的选择与目标人群依从性、筛查覆盖率及病变检出率密切相关。目前成熟的胃癌筛查方法包括血清学检查、胃镜检查、液体活检等,筛查模式涵盖了以胃镜普查为主的“一步法策略”和血清学检查与胃镜检查组合的“序贯式策略”。本文回顾分析当前主要胃癌筛查方法和模式的特点及性能,并借鉴其他癌种筛查方法的优势提出胃癌筛查的潜在策略,以期为胃癌筛查的可行路径提供参考,进一步助力我国胃癌筛查规范化建设。

     

    Abstract: As China is a country with high incidence of gastric cancer, it is of great significance to actively carry out mass screening at the population level for early diagnosis and treatment of gastric cancer. Current practical experience shows that the selection of screening methods and patterns is closely related to the compliance of the target population, screening coverage and lesion detection rate. Currently, mature gastric cancer screening methods include serologic examination, gastroscopy, liquid biopsy, etc., while screening patterns include "one-step strategy" based on gastroscopy and "sequential strategy" combining serologic examination and gastroscopy. The purpose of this paper is to review the current mainstream status of gastric cancer screening methods and patterns, and to draw on the potential advantages of other cancer screening methods, with a view to providing reference for the exploration of feasible pathways for gastric cancer screening, and further contributing to the standardization of gastric cancer screening in China.

     

  • 胃癌是常见的消化道肿瘤,严重威胁人民群众的生命健康。国际癌症研究所发布的全球癌症发病及死亡数据显示,胃癌发病率、死亡率位居全部癌症的第5位[1]。2022年全球约新增96.8万例胃癌患者,其中约37.1%在中国[1]。胃癌作为年龄相关性疾病,预计发病率将随我国人口老龄化加剧而快速升高,2040年全国新发病例预计将达到100万例[2],极大加重我国卫生体系负担。胃癌预后与诊治时机密切相关,早期胃癌的5年生存率可达90%,而晚期胃癌的5年生存率往往低于30%[3]。早期胃癌往往无特异症状,易被忽视。大量研究表明对胃癌进行早期筛查可以显著改善肿瘤的早诊率和长期生存率[4-5]。韩国对全国40岁以上居民实施早期胃癌筛查计划,使目标人群的胃癌死亡风险降低了21%,并且随着筛查次数的增多,死亡风险进一步降低[6]。我国胃癌患者的早诊率低于10%,约90%的检出胃癌处于进展期[7],早诊率和5年生存率均处于东亚较低水平[8]。我国在胃癌的早诊早治领域面临着严峻的挑战,推动胃癌的早期筛查具有重要意义。本文对当前主流胃癌筛查方法进行综述,探讨阻碍我国当前筛查模式大规模应用的因素及改进措施,并展望胃癌筛查的未来发展方向。

    问卷调查是胃癌高危人群的初步筛查方法,常与胃镜检查结合使用。胃癌筛查的问卷通常包含人口学信息、卫生生活习惯、疾病自然病史和家族病史等信息[9-10]。与血清学方法相比,问卷调查具有低成本、非侵入的优势,因此具有更高的可及性和便捷性;此外,问卷初筛还可以评估目标人群对后续筛查方法的接受度和倾向性[11],有助于了解人群对胃癌和相关筛查的认知情况[12]。需要注意的是,通过问卷获取受访者准确信息依赖受试者对调查信息的正确理解,然而目前基于问卷的胃癌筛查策略难以获得较高的区分精度,在ROC曲线分析中其AUC极少达到0.7[13]。如何在不同习惯风俗和认知程度的人群中保持问卷的高准确性和一致性,并最大程度降低潜在的回忆偏倚,可能是打破问卷筛查固有限制的关键。这也是进一步开展胃癌筛查大队列研究和卫生经济学评估的重要基石。

    目前用于胃癌筛查的血清学检测主要包括胃癌标志物检测和癌前病变指标检测。传统胃癌标志物包括糖类抗原(carbohydrate antigen,CA)19-9、CA72-4、癌胚抗原、甲胎蛋白等,鉴于其在进展期胃癌中的阳性率低于30%,对早期胃癌的检出率低于10%,现已极少使用[14]。胃癌的发展是一个渐进性的过程,从慢性胃炎、肠上皮化生、癌前病变到胃浸润性癌,而幽门螺杆菌(Helicobacter pyloriHp)参与了系列癌前疾病的启动和维持[15]。因此,检测癌前病变指标可以间接筛查胃癌。常见的癌前病变指标包括Hp抗体、胃蛋白酶原Ⅰ/胃蛋白酶原Ⅱ比值(gepsinogen Ⅰ/Ⅱ ratio,PGR)、胃泌素17(gastrin-17,G-17),其胃癌筛查效能已经得到良好的验证。Cai等[16]基于上述指标联合年龄、性别因素构建了“新型胃癌筛查评分系统”,采用该评分系统对中国人群进行大规模筛查可将中高风险人群的胃癌早诊率提升至70.3%,同时显著降低了筛查成本,对破解当前胃癌筛查的困境具有重要意义。

    液体活检通过非侵入性方式提取体液,检测其中的肿瘤衍生成分,是胃癌直接筛查的方法之一。经典的胃癌液体活检标志物包括循环肿瘤细胞(circulating tumor cell,CTC)以及循环肿瘤DNA(circulating tumor DNA,ct-DNA)、细胞游离DNA(cell free DNA,cfDNA)、环状RNA(circular RNA,circRNA)、miRNA、lncRNA等遗传物质,近年来蛋白质等其他种类的标志物也逐渐受到关注[17]。液体活检涵盖了多种样本来源,如胃液、唾液及多种外泌体等,进一步拓展了液体活检的应用前景[18-20]。与传统的血清学检测相比,液体活检具有诸多优势,如更高的特异度和灵敏度[21]、对早期胃癌更敏感[22]以及活检标本在不同环境下均能保持稳定[23]等。然而,由于高昂的检测成本以及有效靶标的缺乏,现阶段仍然难以将液体活检用于大规模胃癌筛查。此外,目前也缺乏相关技术标准以规范化液体活检的采样和检测[24]。部分液体活检胃癌标志物及其检测性能[21, 25-30]表 1

    表  1  部分液体活检胃癌标志物的检测性能
    标志物种类 标志物名称 灵敏度 特异度 AUC 研究来源
    lncRNA B3GALT5-AS1 0.65 0.87 0.82 Feng等,2020[25]
    CTC 0.85 0.90 0.93 Kang等,2017[26]
    cfDNA 甲基化H19,MALAT1 0.69 0.93 0.82 Hu等,2021[27]
    蛋白质 TXNRD1 0.95 0.76 0.95 Zhu等,2022[28]
    circRNA hsa-circRNA-0045602,hsa_-circRNA-0008768,hsa_-circRNA-0007380,hsa_-circRNA-0002019,hsa_-circRNA-0006089,hsa_-circRNA-0034398,hsa_-circRNA-0052001,hsa_-circRNA-0001013 0.89 0.62 0.83 Roy等,2022[29]
    miRNA miRNA-140,miRNA-183,miRNA-30e,miRNA-103a,miRNA-126,miRNA-93,miRNA-142,miRNA-21,miRNA-29c,miRNA-424,miRNA-181a,miRNA-340 0.87 0.68 0.85 So等,2021[21]
    miRNA miRNA-18a,miRNA-181b,miRNA-335 0.72 0.88 0.86 Izumi等,2021[30]
    AUC:曲线下面积;lncRNA:长链非编码RNA;B3GALT5-AS1:1, 3-半乳糖基转移酶-多肽5反义RNA;CTC:循环肿瘤细胞;cfDNA:细胞游离DNA;MALAT1:转移相关性肺腺癌转录本1;TXNRD1:硫氧还蛋白还原酶1;circRNA:环状RNA;hsa:智人;miRNA:微RNA.

    胃镜检查及活检是胃癌确诊的金标准。韩国自2002年起对适龄人群进行胃镜筛查,显著提高了早期胃癌的诊断率[31-32]。然而,常规的白光内镜对早期胃癌的检出率较低[14],为解决此问题,深度学习等人工智能技术被应用于白光内镜图像的识别和病理切片的读片,以此实现优于人眼直接观察的诊断精度,可将漏诊率降低20%以上[33];同时,新型内镜技术如色素内镜、电子染色内镜、放大共聚焦显微内镜等也被广泛应用于病变范围、深度的观察以及组织病理学信息的获取[34],强化了早期胃癌的内镜下表现特征,有助于提升对早期胃癌的评估能力。不耐受常规电子内镜检查的人群还可通过磁控胶囊内镜参与胃癌筛查,磁控胶囊内镜作为一种无痛、便捷的替代方案,其诊断胃部疾病的准确性已被证实与常规电子内镜相当[35]

    “一步法”筛查指采用单一技术手段对胃癌开展直接筛查。“一步法”要求筛查方法具有较高的灵敏度,因此主要采用影像学方法,包括胃镜检查和上消化道X线钡剂造影检查等。由于消化道内镜技术的普及、民众对射线损伤的认知改变[36]及X线钡剂造影检查较胃镜在胃癌筛查中高达2.7倍的成本差距[37],X线钡剂造影检查在胃癌早期筛查中的占比逐渐降低,在“一步法”筛查模式较为成熟的日本,X线钡剂造影检查的比例也已降至不足10%[38-39]。因此,本文对“一步法”的讨论主要针对胃镜检查展开。

    胃镜检查不仅准确性高,还可以同时进行诊断性活检和治疗,因此在胃癌筛查中应用广泛。考虑到胃镜检查的不适、对医师操作的高要求及成本较高等因素,胃镜筛查更适用于高发地区或高风险人群。胃镜筛查降低胃癌高危患者死亡率的作用已得到广泛证实[6, 40]。一项东亚胃癌筛查项目的回顾性研究发现,患者接受胃镜筛查的次数与胃癌死亡风险成反比(接受1次、2次、3次筛查者胃癌死亡风险比分别降低40%、68%、81%)[6]。胃镜检查的频率、筛查的起始年龄均会影响胃镜筛查的收益。一项在中国高危地区开展的针对胃镜筛查频率的研究显示,40~70岁人群每2年进行一次胃镜筛查具有最优的卫生经济效益,且初次筛查越早(40~45岁)成本效益越佳[41]。现有指南推荐对45岁以上人群开展常规胃镜筛查[42],同时年轻人群胃癌发病率持续上升的趋势也值得关注[43]

    与结肠镜筛查能够明确降低结直肠癌发病率和死亡率[44-45]不同,胃镜筛查对胃癌发病率的作用尚存争议。一项meta分析显示,胃镜筛查与胃癌发病率之间的关联没有统计学意义(RR=1.14,95%CI 0.93~1.40)[40]。Gao等[46]认为这一结论可能受到不同研究间设计差异(例如纳入未经过或经过放射学检查的人群作为对照)、选择偏倚(例如有症状的患者更倾向于选择参加内镜组)的影响。胃镜筛查对胃癌发病率的实际效益仍然有待规模更大、设计更严谨、随访周期更长的随机对照研究进一步明确。

    “序贯式”筛查即首先采用简便方法区分胃癌高危人群,然后采用准确性更高的“金标准”方法对高危人群进行精查。“序贯式”筛查模式强调前期筛查方法的便捷性和二次筛查方法的可靠性,且注重整体筛查效益。在胃癌筛查的日常实践中,“序贯式”筛查已经演化为以社会人口学因素+血清学指标为初筛、胃镜检查为精筛的成熟模式[16, 47]。使用血清学指标的“序贯式”筛查具有坚实的数据基础,一项在河北省赞皇县居民中开展的长达14年的随访研究发现,血清胃蛋白酶原(pepsinogen,PG)、Hp抗体异常人群的胃癌发病率高达56%[48]。“序贯式”筛查所采用的血清学危险分层方法经历了最初的“ABC法”(血清PG和Hp抗体)、“新ABC法”(血清PG和G-17)直至近年“新型胃癌筛查评分系统”(血清Hp抗体、PGR、G-17)的演变过程。一项在浙江省开展的多层级比较研究发现,上述3种血清学危险分层方法的胃癌检出率在高危组分别为3.21%、4.10%和7.84%,且“新型胃癌筛查评分系统”在区分高危与中、低危人群方面表现出更好的效果[49]

    相比于以胃镜普查为主要手段的“一步法”策略,“序贯式”筛查策略具有显著的成本效益优势和更高的目标人群依从度,有效缓解了我国胃癌筛查需求与胃镜资源不足的矛盾,减少了目标人群进行胃镜检查的痛苦,更契合大规模人群筛查和低风险地区筛查的需求。按照风险比例计算,使用“新型胃癌筛查评分系统”初筛可减少67%的胃镜检查需求[16]。卫生经济学研究发现,相较于胃镜筛查,首先进行血清学检查进行初筛具有更低的启动门槛和更高的患者依从性[36],更适应我国人口基数庞大、胃癌发病率高、经济发展不平衡的国情。

    以“序贯式”筛查为例,血清学检查高危人群不能及时进行内镜检查是筛查效力降低的重要原因之一。在结直肠癌筛查中,仅有56%的粪便免疫化学检测(fecal immunochemical test,FIT)阳性人群在1年内参与了后续的结肠镜检查[50]。转诊系统的失灵、患者教育的缺乏、内镜检查前准备不充分、患者的客观情况阻碍都可能导致前期血清学检查和后期内镜检查的脱节[51]。此外,胃癌筛查可能造成的风险,如过度诊断、假阳性、胃镜检查的不良反应[52]也可能使目标人群存在心理障碍,阻碍胃癌筛查在更大范围开展。

    基于现实问题,以下措施可在一定程度上改善当前局面:(1)针对前期筛查阳性人群失访失联的问题,应建立完善的信息库,并长期跟踪随访目标人群;(2)针对流程冗杂、转诊不畅的问题,应设立咨询联络专线以提供指引,同时简化人群就诊和转诊的流程;(3)针对目标人群因客观因素难以完成胃癌筛查流程的问题,应加强卫生教育,必要时提供经济及交通支持;(4)明确各部门和人员责任,将胃镜检查的完成率和完成质量纳入考核指标。这些措施有望促进胃癌筛查工作的系统化和规范化,提高筛查模式的整体效力。

    随着不断努力,胃癌筛查覆盖面不足、筛查响应率不高的问题已经得到一定缓解,但筛查完成度不高的困境也逐渐浮现。低筛查完成度会抹消扩大筛查覆盖面的努力,因此,应采取有效措施提高筛查流程的完成率,从而进一步提高筛查效力、凸显筛查价值,让更多人参与胃癌筛查。

    胃癌筛查的规范化建设是一个系统化工程,涉及多个环节和步骤。基于当前实践和专家建议,本文构想的胃癌筛查的规范化流程如下。

    (1)确定筛查目标人群。推荐对年龄为45~74岁且符合以下条件之一的人群进行胃癌筛查:居住在胃癌高发地区、有胃癌家族史、Hp感染阳性、存在不良生活习惯(如吸烟、重度饮酒等)或患有胃癌前病变(如慢性萎缩性胃炎、胃溃疡等)。

    (2)筛查模式和方法。推荐采用“序贯式”胃癌筛查策略,首先结合问卷、人口学因素、常规血清学检查等信息区分高危人群,然后采用“金标准”方法对高危人群进行精筛。推荐使用内镜检查作为精筛的首选方法,包括普通白光内镜检查和特殊内镜技术(如窄带成像技术结合放大内镜等)。对于不能耐受常规内镜检查者,可考虑使用磁控胶囊胃镜。

    (3)后续管理。对于低风险或筛查结果为阴性的个体,应进行健康教育并提醒定期复查。对于高风险或筛查发现的癌前病变或胃癌患者,应根据临床诊疗要求进行治疗和随访。

    (4)质量控制。确保问卷填写全面且合理、样本获取规范、检测流程标准,确保内镜检查过程至少持续7 min,并对胃内部进行系统观察;推荐设定胃癌早期诊断率作为质控指标。

    (5)数据管理。建立胃癌筛查数据库,收集和分析筛查数据,以评估筛查效果、改进筛查策略,同时注重目标人群的隐私保护。

    (6)公众教育和参与。加强卫生教育,提高公众对胃癌风险因素及胃癌筛查重要性的认识,鼓励目标人群积极参与筛查。

    (7)政策支持和资源配置。确保有足够的医疗资源和政策支持来实施胃癌筛查项目。

    (8)研究与创新。在一般人群中建设规范的胃癌筛查队列,建设胃癌筛查样本库,持续进行胃癌筛查相关的研究,探索新的生物标志物和筛查技术,以提高筛查的准确性和效率。

    筛查方法的侵入性、可靠性和成本效益共同决定了最终的筛查模式[53]。现有的胃癌筛查模式从以胃镜和X线钡剂造影为主的“一步法”过渡到血清学+胃镜的“序贯式”筛查的演变,检出率、成本效益、人群依从性逐步提升,但仍存在一定优化空间。本文试借鉴其他癌症的筛查方法与模式,拓展胃癌筛查的思路。

    自采样、自检测的方法在宫颈癌和结直肠癌的筛查中得到广泛应用。自行宫颈刮片检测人乳头瘤病毒已成为宫颈癌筛查的途径之一[54],自行取样检测的FIT试剂盒也被应用于结直肠癌筛查中[55-56]。自采样比前往诊疗机构进行取样检测更加便捷,提高了相关人群的依从性和参与度[57],扩大了的筛查覆盖面[58-59],在医疗资源相对匮乏的地区有一定优势。

    自采样和自检测的模式对靶标和样本的灵敏度与特异度、样本在环境中的稳定性提出了更高要求。利用唾液和舌苔的生物学特征进行胃癌筛查的探索,拓展了这一模式应用于胃癌筛查的可能性。Swarup等[19]从唾液样本中提取胃癌特异性cfDNA,为液体活检提供了新的途径;Yuan等[60]试图利用机器学习方法识别舌苔图像的特征,以此区分胃癌患者和健康人群。自采样在癌症筛查中的大规模应用有赖于足够简便易行的采样方法和灵敏度、特异度足够高的检测指标。源自唾液的cfDNA样本和舌苔图像基本符合自采样的客观要求,但当前研究的样本量较小,其可靠性仍然需要更严谨、规模更大的临床研究加以验证。值得注意的是,一项对结直肠癌筛查方法的分析发现,尽管单次无增强CT的结直肠癌检出效能高于FIT,但一般人群对FIT检测的接受度和依从性更高,3次FIT检测的癌症检出率也超过了单次CT[61]。在实际应用中,灵敏度略低的筛查方法若同时具备更高的患者接受度和参与度,其整体效能可能优于理论场景下性能更佳的方法。

    机会性筛查特指以医院就诊者为基础,将常规诊疗与疾病筛查结合的筛查模式。机会性筛查的对象指无特异性症状,但根据社会人口学因素、生活习惯、家族史、既往史判断可能存在患病风险的人群。一项新加坡的研究显示了机会性筛查在胃癌筛查中的有效性。该研究对40岁以上、无特异性症状的结肠镜检查对象施行胃镜机会性筛查,胃癌癌前病变和胃肿瘤病变的检出率分别为12.3%和0.4%[62],验证了结肠镜+胃镜机会性筛查的良好效果。此类机会性筛查模式避免了患者再次经历胃排空等事前准备的痛苦,提高了患者的依从性[63-64]

    现有的胃癌机会性筛查模式仍然要求患者参与血清学检测+胃镜精筛的流程,并不能切实减轻患者的负担。Cao等[65]利用深度学习方法首创非增强CT筛查胰腺癌的模型,并探索了胸部CT检查联合胰腺癌机会性筛查的潜力。这一研究不仅实现了无痛、无创的胰腺癌筛查,而且利用胰腺的解剖学位置联合胸部CT检查和胰腺癌机会性筛查,对当前仍以胃镜检查为主的胃癌机会性筛查极具借鉴意义。然而,当下针对胃癌的X线、CT等影像学和其他放射学检查仍然存在较高的异质性和较低的检出率[66],更便捷、更普适的一般检查联合胃癌筛查的新方法、新模式仍然有待开发。

    患者的病历和医保系统等医疗健康信息记录囊括了关键的病史和生理、病理学指标,既往医疗信息的挖掘和分析也是癌症筛查的方向之一。Rubenstein等[67]基于美国全国范围电子健康记录开发了K-ECAN模型,该模型利用既往处方和检验记录评估食管癌风险,ROC曲线分析显示其AUC可达0.85。这一方法的缺点在于患者必须主动购药、求医,才能留下可供分析的记录,不能与癌症早期可能无特异性症状的特征相匹配。基于此,Pereira等[68]提出根据目标人群在社交媒体上自我描述的症状和生活习惯寻找胰腺导管腺癌高危人群的设想。对应到胃癌筛查中,自我陈述存在相应危险因素的社交媒体用户都可能是这一方法的潜在受益者。尽管病历、医保系统及患者在社交媒体上披露的健康相关信息为癌症筛查提供了新的视角,但这些数据固有的随机性、滞后性成为数据收集和标准化的障碍,此外,医学术语和患者表述之间的差异及对用户隐私的保护也可能成为实际应用的难点。因此,将医疗/网络信息用于癌症筛查的方法在现阶段难以作为大规模应用的正式筛查方法,更适合作为寻找癌症高危人群的辅助手段。

    胃癌的早期筛查是提高胃癌早诊率、降低死亡率的重要手段之一。随着新的标志物不断被发现,以及检验技术、影像技术和成本效益核算方法的不断发展,胃癌筛查方法日新月异。成熟的胃癌筛查方法不仅应具备较高的灵敏度和特异度,还应有较好的人群依从性和响应率。对筛查方法进行组合,构建合适的筛查模式,以适应目标人群和地区的一般情况,对于提高胃癌筛查成功率至关重要。现行的“序贯式”筛查模式将社会人口学特征/血清学指标与胃镜检查有机结合,提高了胃癌筛查的检出率、依从性和成本效益。未来,通过进一步开发检验和影像技术、实施更细致全面的流行病学调查,有望开发出侵袭性更低、更可靠的胃癌筛查方法,构建成本效益和依从性更高的筛查模式。

  • 表  1   部分液体活检胃癌标志物的检测性能

    标志物种类 标志物名称 灵敏度 特异度 AUC 研究来源
    lncRNA B3GALT5-AS1 0.65 0.87 0.82 Feng等,2020[25]
    CTC 0.85 0.90 0.93 Kang等,2017[26]
    cfDNA 甲基化H19,MALAT1 0.69 0.93 0.82 Hu等,2021[27]
    蛋白质 TXNRD1 0.95 0.76 0.95 Zhu等,2022[28]
    circRNA hsa-circRNA-0045602,hsa_-circRNA-0008768,hsa_-circRNA-0007380,hsa_-circRNA-0002019,hsa_-circRNA-0006089,hsa_-circRNA-0034398,hsa_-circRNA-0052001,hsa_-circRNA-0001013 0.89 0.62 0.83 Roy等,2022[29]
    miRNA miRNA-140,miRNA-183,miRNA-30e,miRNA-103a,miRNA-126,miRNA-93,miRNA-142,miRNA-21,miRNA-29c,miRNA-424,miRNA-181a,miRNA-340 0.87 0.68 0.85 So等,2021[21]
    miRNA miRNA-18a,miRNA-181b,miRNA-335 0.72 0.88 0.86 Izumi等,2021[30]
    AUC:曲线下面积;lncRNA:长链非编码RNA;B3GALT5-AS1:1, 3-半乳糖基转移酶-多肽5反义RNA;CTC:循环肿瘤细胞;cfDNA:细胞游离DNA;MALAT1:转移相关性肺腺癌转录本1;TXNRD1:硫氧还蛋白还原酶1;circRNA:环状RNA;hsa:智人;miRNA:微RNA.
  • [1] BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. DOI: 10.3322/caac.21834.
    [2] ZHANG T, CHEN H, YIN X, et al. Changing trends of disease burden of gastric cancer in China from 1990 to 2019 and its predictions: findings from Global Burden of Disease Study[J]. Chin J Cancer Res, 2021, 33(1): 11-26. DOI: 10.21147/j.issn.1000-9604.2021.01.02.
    [3] ZENG H, RAN X, AN L, et al. Disparities in stage at diagnosis for five common cancers in China: a multicentre, hospital-based, observational study[J]. Lancet Public Health, 2021, 6(12): e877-e887. DOI: 10.1016/S2468-2667(21)00157-2.
    [4] KATAI H, ISHIKAWA T, AKAZAWA K, et al. Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100, 000 patients from the nationwide registry of the Japanese Gastric Cancer Association (2001-2007)[J]. Gastric Cancer, 2018, 21(1): 144-154. DOI: 10.1007/s10120-017-0716-7.
    [5] HONG S, WON Y J, LEE J J, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2018[J]. Cancer Res Treat, 2021, 53(2): 301-315. DOI: 10.4143/crt.2021.291.
    [6] JUN J K, CHOI K S, LEE H Y, et al. Effectiveness of the Korean national cancer screening program in reducing gastric cancer mortality[J]. Gastroenterology, 2017, 152(6): 1319-1328.e7. DOI: 10.1053/j.gastro.2017.01.029.
    [7] SUGANO K. Screening of gastric cancer in Asia[J]. Best Pract Res Clin Gastroenterol, 2015, 29(6): 895-905. DOI: 10.1016/j.bpg.2015.09.013.
    [8] ZENG H, CHEN W, ZHENG R, et al. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries[J]. Lancet Glob Health, 2018, 6(5): e555-e567. DOI: 10.1016/S2214-109X(18)30127-X.
    [9] CHARVAT H, SASAZUKI S, INOUE M, et al. Prediction of the 10-year probability of gastric cancer occurrence in the Japanese population: the JPHC study cohort Ⅱ[J]. Int J Cancer, 2016, 138(2): 320-331. DOI: 10.1002/ijc.29705.
    [10] ZHU X, LV J, ZHU M, et al. Development, validation, and evaluation of a risk assessment tool for personalized screening of gastric cancer in Chinese populations[J]. BMC Med, 2023, 21(1): 159. DOI: 10.1186/s12916-023-02864-0.
    [11] 党旖旎, 许年珍, 严谨, 等. 江苏南部地区早期胃癌及癌前病变筛查结果及分析[J]. 中华健康管理学杂志, 2018, 4(1): 26-31. DOI: 10.3760/cma.j.issn.1674-0815.2018.01.006.
    [12] CHEN X, ZE Y, YI W, et al. Barriers to upper gastrointestinal screening among the general population in high-prevalence areas: a cross-sectional study[J]. JBI Evid Implement, 2024, 22(2): 218-227. DOI: 10.1097/XEB.0000000000000396.
    [13] ZHOU R, ZHENG H, LIU M, et al. Development and validation of a questionnaire-based risk scoring system to identify individuals at high risk for gastric cancer in Chinese populations[J]. Chin J Cancer Res, 2021, 33(6): 649-658. DOI: 10.21147/j.issn.1000-9604.2021.06.02.
    [14] 杜奕奇, 蔡全才, 廖专, 等. 中国早期胃癌筛查流程专家共识意见(草案)(2017年, 上海)[J]. 胃肠病学, 2018, 23(2): 92-97. DOI: 10.3760/cma.j.issn.0254-1432.2018.02.006.
    [15] CORREA P, HAENSZEL W, CUELLO C, et al. A model for gastric cancer epidemiology[J]. Lancet, 1975, 2(7924): 58-60. DOI: 10.1016/s0140-6736(75)90498-5.
    [16] CAI Q, ZHU C, YUAN Y, et al. Development and validation of a prediction rule for estimating gastric cancer risk in the Chinese high-risk population: a nationwide multicentre study[J]. Gut, 2019, 68(9): 1576-1587. DOI: 10.1136/gutjnl-2018-317556.
    [17] SHINOZUKA T, KANDA M, KODERA Y. Site-specific protein biomarkers in gastric cancer: a comprehensive review of novel biomarkers and clinical applications[J]. Expert Rev Mol Diagn, 2023, 23(8): 701-712. DOI: 10.1080/14737159.2023.2232298.
    [18] FELÍPEZ N, MONTORI S, MENDIZURI N, et al. The human gastric juice: a promising source for gastric cancer biomarkers[J]. Int J Mol Sci, 2023, 24(11): 9131. DOI: 10.3390/ijms24119131.
    [19] SWARUP N, CHENG J, CHOI I, et al. Multi-faceted attributes of salivary cell-free DNA as liquid biopsy biomarkers for gastric cancer detection[J]. Biomark Res, 2023, 11(1): 90. DOI: 10.1186/s40364-023-00524-2.
    [20] ZHANG Z, WU H, CHONG W, et al. Liquid biopsy in gastric cancer: predictive and prognostic biomarkers[J]. Cell Death Dis, 2022, 13(10): 903. DOI: 10.1038/s41419-022-05350-2.
    [21] SO JBY, KAPOOR R, ZHU F, et al. Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population[J]. Gut, 2021, 70(5): 829-837. DOI: 10.1136/gutjnl-2020-322065.
    [22] XIE W, SURYAPRAKASH S, WU C, et al. Trends in the use of liquid biopsy in oncology[J]. Nat Rev Drug Discov, 2023, 22(8): 612-613. DOI: 10.1038/d41573-023-00111-y.
    [23] GRIZZI G, SALATI M, BONOMI M, et al. Circulating tumor DNA in gastric adenocarcinoma: future clinical applications and perspectives[J]. Int J Mol Sci, 2023, 24(11): 9421. DOI: 10.3390/ijms24119421.
    [24] MA S, ZHOU M, XU Y, et al. Clinical application and detection techniques of liquid biopsy in gastric cancer[J]. Mol Cancer, 2023, 22(1): 7. DOI: 10.1186/s12943-023-01715-z.
    [25] FENG W, ZONG W, LI Y, et al. Abnormally expressed long noncoding RNA B3GALT5-AS1 may serve as a biomarker for the diagnostic and prognostic of gastric cancer[J]. J Cell Biochem, 2020, 121(1): 557-565. DOI: 10.1002/jcb.29296.
    [26] KANG H M, KIM G H, JEON H K, et al. Circulating tumor cells detected by lab-on-a-disc: role in early diagnosis of gastric cancer[J]. PLoS One, 2017, 12(6): e0180251. DOI: 10.1371/journal.pone.0180251.
    [27] HU D, LOU X, MENG N, et al. Peripheral blood-based DNA methylation of long non-coding RNA H19 and metastasis-associated lung adenocarcinoma transcript 1 promoters are potential non-invasive biomarkers for gastric cancer detection[J]. Cancer Control, 2021, 28: 10732748211043667. DOI: 10.1177/10732748211043667.
    [28] ZHU Y, HU Y, ZHU X, et al. Plasma thioredoxin reductase: a potential diagnostic biomarker for gastric cancer[J]. Carcinogenesis, 2022, 43(8): 736-745. DOI: 10.1093/carcin/bgac052.
    [29] ROY S, KANDA M, NOMURA S, et al. Diagnostic efficacy of circular RNAs as noninvasive, liquid biopsy biomarkers for early detection of gastric cancer[J]. Mol Cancer, 2022, 21(1): 42. DOI: 10.1186/s12943-022-01527-7.
    [30] IZUMI D, ZHU Z, CHEN Y, et al. Assessment of the diagnostic efficiency of a liquid biopsy assay for early detection of gastric cancer[J]. JAMA Netw Open, 2021, 4(8): e2121129. DOI: 10.1001/jamanetworkopen.2021.21129.
    [31] CHOI K S, JUN J K, SUH M, et al. Effect of endoscopy screening on stage at gastric cancer diagnosis: results of the National Cancer Screening Programme in Korea[J]. Br J Cancer, 2015, 112(3): 608-612. DOI: 10.1038/bjc.2014.608.
    [32] KANG E, CHOI K S, JUN J K, et al. Trends in cancer-screening rates in Korea: findings from the national cancer screening survey, 2004-2023[J]. Cancer Res Treat, 2025, 57(1): 28-38. DOI: 10.4143/crt.2024.325.
    [33] WU L, SHANG R, SHARMA P, et al. Effect of a deep learning-based system on the miss rate of gastric neoplasms during upper gastrointestinal endoscopy: a single-centre, tandem, randomised controlled trial[J]. Lancet Gastroenterol Hepatol, 2021, 6(9): 700-708. DOI: 10.1016/S2468-1253(21)00216-8.
    [34] HOFFMAN A, MANNER H, REY J W, et al. A guide to multimodal endoscopy imaging for gastrointestinal malignancy-an early indicator[J]. Nat Rev Gastroenterol Hepatol, 2017, 14(7): 421-434. DOI: 10.1038/nrgastro.2017.46.
    [35] LIAO Z, HOU X, LIN-HU E Q, et al. Accuracy of magnetically controlled capsule endoscopy, compared with conventional gastroscopy, in detection of gastric diseases[J]. Clin Gastroenterol Hepatol, 2016, 14(9): 1266-1273.e1. DOI: 10.1016/j.cgh.2016.05.013.
    [36] 周显祝, 朱春平, 高野, 等. 胃癌筛查的卫生经济学评价进展[J]. 中华健康管理学杂志, 2020, 6(1): 84-88. DOI: 10.3760/cma.j.issn.1674-0815.2020.01.018.
    [37] LEE H Y, PARK E C, JUN J K, et al. Comparing upper gastrointestinal X-ray and endoscopy for gastric cancer diagnosis in Korea[J]. World J Gastroenterol, 2010, 16(2): 245-250. DOI: 10.3748/wjg.v16.i2.245.
    [38] MONDEN M. The basic plan to promote cancer control in Japan[J]. Gan To Kagaku Ryoho, 2013, 40(5): 559-564.
    [39] GOTODA T, ISHIKAWA H, KUSANO C, et al. Randomized controlled trial comparing the costs of gastric cancer screening systems between serological risk-based upper gastrointestinal endoscopy and the existing barium photofluorography: gastric cancer screening labeled by serum examination in place of aged gastric cancer organized screening systems (GALAPAGOS study)[J]. Gastric Cancer, 2024, 27(1): 36-48. DOI: 10.1007/s10120-023-01449-3.
    [40] ZHANG X, LI M, CHEN S, et al. Endoscopic screening in Asian countries is associated with reduced gastric cancer mortality: a meta-analysis and systematic review[J]. Gastroenterology, 2018, 155(2): 347-354.e9. DOI: 10.1053/j.gastro.2018.04.026.
    [41] XIA R, ZENG H, LIU W, et al. Estimated cost-effectiveness of endoscopic screening for upper gastrointestinal tract cancer in high-risk areas in China[J]. JAMA Netw Open, 2021, 4(8): e2121403. DOI: 10.1001/jamanetworkopen.2021.21403.
    [42] 赫捷, 陈万青, 李兆申, 等. 中国胃癌筛查与早诊早治指南(2022, 北京)[J]. 中华肿瘤杂志, 2022, 44(7): 634-666. DOI: 10.3760/cma.j.cn112152-20220617-0043.
    [43] SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
    [44] PAN J, XIN L, MA Y F, et al. Colonoscopy reduces colorectal cancer incidence and mortality in patients with non-malignant findings: a meta-analysis[J]. Am J Gastroenterol, 2016, 111(3): 355-365. DOI: 10.1038/ajg.2015.418.
    [45] YANG Y, GAO Z, HUANG A, et al. Epidemiology and early screening strategies for colorectal cancer in China[J]. Chin J Cancer Res, 2023, 35(6): 606-617. DOI: 10.21147/j.issn.1000-9604.2023.06.05.
    [46] GAO Y, XI H, CHEN L. Does endoscopic screening really not alter the incidence of gastric cancer?[J]. Gastroenterology, 2021, 161(1): 374-375. DOI: 10.1053/j.gastro.2018.07.060.
    [47] WATABE H, MITSUSHIMA T, YAMAJI Y, et al. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study[J]. Gut, 2005, 54(6): 764-768. DOI: 10.1136/gut.2004.055400.
    [48] ZHANG X, XUE L, XING L, et al. Low serum pepsinogen Ⅰ and pepsinogen Ⅰ/Ⅱ ratio and Helicobacter pylori infection are associated with increased risk of gastric cancer: 14-year follow up result in a rural Chinese community[J]. Int J Cancer, 2012, 130(7): 1614-1619. DOI: 10.1002/ijc.26172.
    [49] 倪栋琼, 吕宾, 包海标, 等. 不同血清学危险分层方法在人群早期胃癌筛查中的比较研究[J]. 中华内科杂志, 2019, 58(4): 294-300. DOI: 10.3760/cma.j.issn.0578-1426.2019.04.011.
    [50] MOHL J T, CIEMINS E L, MILLER-WILSON L A, et al. Rates of follow-up colonoscopy after a positive stool-based screening test result for colorectal cancer among health care organizations in the US, 2017-2020[J]. JAMA Netw Open, 2023, 6(1): e2251384. DOI: 10.1001/jamanetworkopen.2022.51384.
    [51] ISSAKA R B, BELL-BROWN A, SNYDER C, et al. Perceptions on barriers and facilitators to colonoscopy completion after abnormal fecal immunochemical test results in a safety net system[J]. JAMA Netw Open, 2021, 4(8): e2120159. DOI: 10.1001/jamanetworkopen.2021.20159.
    [52] HAMASHIMA C. Benefits and harms of endoscopic screening for gastric cancer[J]. World J Gastroenterol, 2016, 22(28): 6385-6392. DOI: 10.3748/wjg.v22.i28.6385.
    [53] BORNSCHEIN J, RUGGE M. Bright future for endoscopy: the new frontier of gastric cancer secondary prevention[J]. Gut, 2020, 69(10): 1723-1724. DOI: 10.1136/gutjnl-2020-321570.
    [54] GIORGI ROSSI P, FORTUNATO C, BARBARINO P, et al. Self-sampling to increase participation in cervical cancer screening: an RCT comparing home Mailing, distribution in pharmacies, and recall letter[J]. Br J Cancer, 2015, 112(4): 667-675. DOI: 10.1038/bjc.2015.11.
    [55] O'SULLIVAN I, ORBELL S. Self-sampling in screening to reduce mortality from colorectal cancer: a qualitative exploration of the decision to complete a faecal occult blood test (FOBT)[J]. J Med Screen, 2004, 11(1): 16-22. DOI: 10.1177/096914130301100105.
    [56] ZHAO S, HE Z, SUI X, et al. Real-world stool-based syndecan-2 methylation test improved detection of advanced colorectal neoplasia for colorectal cancer screening: a prospective, multicenter, community-based study[J]. Gastroenterology, 2024, 167(3): 611-614.e7. DOI: 10.1053/j.gastro.2024.04.019.
    [57] WINER R L, LIN J, ANDERSON M L, et al. Strategies to increase cervical cancer screening with mailed human papillomavirus self-sampling kits: a randomized clinical trial[J]. JAMA, 2023, 330(20): 1971-1981. DOI: 10.1001/jama.2023.21471.
    [58] LE GOFF J, LE DUC-BANASZUK A S, LEFEUVRE C, et al. Acceptability to healthcare professionals of home-based HPV self-sampling for cervical screening: a French qualitative study conducted in an area with low access to health services[J]. Cancers (Basel), 2023, 15(21): 5163. DOI: 10.3390/cancers15215163.
    [59] HONG S, SHIN H Y, LEE B, et al. Increase in the colorectal cancer screening rate by a round-mailed fecal immunochemical testing kit and associated factors in underserved regions of Korea: a community-based intervention study[J]. Gut Liver, 2020, 14(3): 323-330. DOI: 10.5009/gnl19124.
    [60] YUAN L, YANG L, ZHANG S, et al. Development of a tongue image-based machine learning tool for the diagnosis of gastric cancer: a prospective multicentre clinical cohort study[J]. EClinicalMedicine, 2023, 57: 101834. DOI: 10.1016/j.eclinm.2023.101834.
    [61] MANG T. CT colonography in organised population-based colorectal cancer screening[J]. Lancet Gastroenterol Hepatol, 2022, 7(11): 975-977. DOI: 10.1016/S2468-1253(22)00299-0.
    [62] LAU J W L, KHOO M J W, LEONG X H, et al. Opportunistic upper endoscopy during colonoscopy as a screening strategy for countries with intermediate gastric cancer risk[J]. J Gastroenterol Hepatol, 2021, 36(4): 1081-1087. DOI: 10.1111/jgh.15290.
    [63] KIM B J, HEO C, KIM B K, et al. Effectiveness of gastric cancer screening programs in South Korea: organized vs opportunistic models[J]. World J Gastroenterol, 2013, 19(5): 736-741. DOI: 10.3748/wjg.v19.i5.736.
    [64] LUU X Q, LEE K, JUN J K, et al. Socioeconomic inequality in organized and opportunistic screening for gastric cancer: results from the Korean National Cancer Screening Survey 2009-2022[J]. Front Public Health, 2023, 11: 1256525. DOI: 10.3389/fpubh.2023.1256525.
    [65] CAO K, XIA Y, YAO J, et al. Large-scale pancreatic cancer detection via non-contrast CT and deep learning[J]. Nat Med, 2023, 29(12): 3033-3043. DOI: 10.1038/s41591-023-02640-w.
    [66] CHEN Q, ZHANG L, LIU S, et al. Radiomics in precision medicine for gastric cancer: opportunities and challenges[J]. Eur Radiol, 2022, 32(9): 5852-5868. DOI: 10.1007/s00330-022-08704-8.
    [67] RUBENSTEIN J H, FONTAINE S, MACDONALD P W, et al. Predicting incident adenocarcinoma of the esophagus or gastric cardia using machine learning of electronic health records[J]. Gastroenterology, 2023, 165(6): 1420-1429. e10. DOI: 10.1053/j.gastro.2023.08.011.
    [68] PEREIRA S P, OLDFIELD L, NEY A, et al. Early detection of pancreatic cancer[J]. Lancet Gastroenterol Hepatol, 2020, 5(7): 698-710. DOI: 10.1016/S2468-1253(19)30416-9.
WeChat 点击查看大图
表(1)
出版历程
  • 收稿日期:  2024-05-10
  • 接受日期:  2024-10-30

目录

    /

    返回文章
    返回